At TTCM we have long been advocating the undervaluation that we see in the Swiss drug maker Novartis.  The company is valued as though it has no growth prospects, but when you look at the pipeline, and the different components of the company, we believe that they have the ability to grow EPS by 7-10%...Read More

On December 19th I sent out an email discussing the unbelievably cheap valuations that we were seeing, which you can see from the forwarded email below.  This is just a quick update on how they are faring.  The point is not to get overly excited, just as we don’t want to get overly pessimistic when...Read More

Today we had our Monday Morning Investment Meeting, and as a firm we are amazed at the valuations that we are finding.  Below you’ll find a sampling of some of our largest positions moving into 2012.  Never before has it been so easy to find profitable companies, where earnings are likely to grow, at a...Read More